Peter A. Smith

发表

A targeted boost-and-sort immunization strategy using Escherichia coli BamA identifies rare growth inhibitory antibodies

D. Seshasayee, Jack Bevers, G. Nakamura, 2018, Scientific Reports.

Combating bacteria and drug resistance by inhibiting mechanisms of persistence and adaptation

Floyd E Romesberg, F. Romesberg, Peter A. Smith, 2007, Nature Chemical Biology.

Monoclonal antibody targeting the β-barrel assembly machine of Escherichia coli is bactericidal

D. Seshasayee, G. Nakamura, J. Payandeh, 2018, Proceedings of the National Academy of Sciences.

Optimized arylomycins are a new class of Gram-negative antibiotics

Min Xu, D. Yan, Min Xu, 2018, Nature.

Axinellamines as Broad-Spectrum Antibacterial Agents: Scalable Synthesis and Biology

F. Romesberg, Peter A. Smith, T. Steed, 2014, Journal of the American Chemical Society.

Synthesis and biological characterization of arylomycin B antibiotics.

F. Romesberg, Peter A. Smith, T. C. Roberts, 2011, Journal of natural products.

Initial efforts toward the optimization of arylomycins for antibiotic activity.

F. Romesberg, Peter A. Smith, Jian Liu, 2011, Journal of medicinal chemistry.

Massive antibody discovery used to probe structure–function relationships of the essential outer membrane protein LptD

D. Seshasayee, Jack Bevers, G. Nakamura, 2019, eLife.

Optimized arylomycins are a new class of Gram-negative antibiotics

Min Xu, D. Yan, W. Phung, 2018, Nature.

Mechanism of Action of the Arylomycin Antibiotics and Effects of Signal Peptidase I Inhibition

F. Romesberg, Peter A. Smith, 2012, Antimicrobial Agents and Chemotherapy.

In Vitro Activities of Arylomycin Natural-Product Antibiotics against Staphylococcus epidermidis and Other Coagulase-Negative Staphylococci

F. Romesberg, Peter A. Smith, Michael E. Powers, 2010, Antimicrobial Agents and Chemotherapy.

Structural and initial biological analysis of synthetic arylomycin A2.

F. Romesberg, Peter A. Smith, R. Cirz, 2007, Journal of the American Chemical Society.

A Putative Bacterial ABC Transporter Circumvents the Essentiality of Signal Peptidase

Shailesh V. Date, Z. Modrušan, D. Yan, 2016, mBio.

Type I Signal Peptidase and Protein Secretion in Staphylococcus epidermidis

G. Siuzdak, S. Trauger, F. Romesberg, 2010, Journal of bacteriology.

Potent Killing of Pseudomonas aeruginosa by an Antibody-Antibiotic Conjugate

D. Seshasayee, G. Nakamura, J. Payandeh, 2021, mBio.

A targeted boost-and-sort immunization strategy using Escherichia coli BamA identifies rare growth inhibitory antibodies

D. Seshasayee, Jack Bevers, G. Nakamura, 2018, Scientific Reports.

Broad-spectrum antibiotic activity of the arylomycin natural products is masked by natural target mutations.

F. Romesberg, Peter A. Smith, Tucker C. Roberts, 2010, Chemistry & biology.

The Escherichia coli β-Barrel Assembly Machinery Is Sensitized to Perturbations under High Membrane Fluidity

R. Vij, S. Rutherford, J. T. Koerber, 2018, Journal of bacteriology.

Inhibition of Protein Secretion in Escherichia coli and Sub-MIC Effects of Arylomycin Antibiotics

B. Cravatt, M. Dix, F. Romesberg, 2018, Antimicrobial Agents and Chemotherapy.

Efforts toward broadening the spectrum of arylomycin antibiotic activity.

F. Romesberg, Peter A. Smith, Jian Liu, 2013, Bioorganic & medicinal chemistry letters.

Synthesis and characterization of the arylomycin lipoglycopeptide antibiotics and the crystallographic analysis of their complex with signal peptidase.

C. Luo, M. Page, M. Paetzel, 2011, Journal of the American Chemical Society.

Single-molecule nanopore sequencing reveals extreme target copy number heterogeneity in arylomycin-resistant mutants

S. Durinck, J. Kaminker, Joseph Guillory, 2020, Proceedings of the National Academy of Sciences.

Mechanism of Action of the Arylomycin Antibiotics and Effects of Signal Peptidase I Inhibition

F. Romesberg, Peter A. Smith, 2012, Antimicrobial Agents and Chemotherapy.